BioStock: Saniona's CEO comments on the recent news
Saniona is advancing its treatments for epilepsy and neurological disorders, with SAN2355 - a selective epilepsy therapy - now in GMP-manufacturing and toxicology studies, aiming for a clinical trial application by late 2025. Meanwhile, Saniona and Acadia Pharmaceuticals has completed two phase I MAD cohorts for ACP-711, formerly SAN711, confirming its safety in healthy volunteers. In addition, from March 18 to April 1, 2025, Saniona's TO4 warrant program could raise up to SEK 188.4 million. We spoke with CEO Thomas Feldthus to learn more.
Read the full interview with Thomas Feldthus at biostock.se:
https://www.biostock.se/en/2025/03/sanionas-ceo-comments-on-the-recent-news/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/